New answer by Radiation Oncologist at Premiere Radiation Oncology (August 3, 2023)
Agree with the answers above and with some nuance. Completion of the phase III trials will be decisive in IO benefit in early-stage non-small cell lung cancer (ES-NSCLC). Howe...